# Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

> **NCT06463587** · PHASE3 · RECRUITING · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 264 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **OTHER:** Placebo
- **DRUG:** Cladribine Low Dose
- **DRUG:** Cladribine High Dose

## Key facts

- **NCT ID:** NCT06463587
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2028-05-19
- **Final completion:** 2030-08-19
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463587, "Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06463587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*